{
    "clinical_study": {
        "@rank": "53656", 
        "arm_group": [
            {
                "arm_group_label": "Baracle Tab.\u00ae", 
                "arm_group_type": "Experimental", 
                "description": "(It can be also placebo) dosage: 2 tablets daily for 48 weeks"
            }, 
            {
                "arm_group_label": "Baraclude Tab.\u00ae", 
                "arm_group_type": "Experimental", 
                "description": "(It can be also placebo) dosage: 2 tablets daily for 48 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a multicenter, double blind, active-controlled, randomized, parallel group study to\n      demonstrate the anti-viral activity and safety of Baracle Tab. and Baraclude Tab. for\n      patients with HBeAg Chronic Hepatitis B. The subject will receive two tablets daily for 48\n      days."
        }, 
        "brief_title": "Baracle Tab. \u00ae Versus Baraclude Tab.\u00ae for Patients With HBeAg Chronic Hepatitis B", 
        "condition": "HBeAg-Positive Chronic Hepatitis B", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis B", 
                "Hepatitis, Chronic", 
                "Hepatitis B, Chronic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects with HbeAg Chronic Hepatitis B for at least six months starting from the\n             Screening visit\n\n          -  Subjects with HBsAg-Positive diagnosed at the screening visit\n\n          -  Subjects with HBeAg-Positive or HBeAg-negative diagnosed at the screening visit\n\n          -  For those who were diagnosed HBeAg-Positive, HBV DNA level should be equal or more\n             than 1x10^5 copies/ml\n\n          -  For those who were diagnosed HBeAg-Negative, HBV DNA level should be equal or more\n             than 1x10^5 copies/ml\n\n          -  Subjects who were NOT administrated any anti-viral agents including interferon or\n             pegylated interferon\n\n        Exclusion Criteria:\n\n          -  Subjects with HCV, HDV or HIV\n\n          -  Subjects with decompensated liver disease who have more than 2.5mg/dl of total\n             bilirubin, longer than 3 seconds of prothrombin time, less than 30g/l of serum\n             albumin\n\n          -  With medical history of hemorrhage, hepatic encephalopathy, or dyshepatia due to\n             ascites, jaundice, varicose vein\n\n          -  Less than 50ml/min of creatinine clearance diagnosed at the screening visit\n\n          -  More than 50 ng/ml of alpha-fetoprotein at the screening visit\n\n          -  Involved in other studies"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "116", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 28, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01913431", 
            "org_study_id": "ETV_HB_IV"
        }, 
        "intervention": [
            {
                "arm_group_label": "Baracle Tab.\u00ae", 
                "intervention_name": "Baracle Tab.\u00ae", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Baraclude Tab.\u00ae", 
                "intervention_name": "Baraclude Tab.\u00ae", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Entecavir"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "July 30, 2013", 
        "location": {
            "contact": {
                "email": "irb@amc.seoul.kr", 
                "last_name": "Han Chu Lee, M.D", 
                "phone": "82-2-3010-7166"
            }, 
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of", 
                    "zip": "138-736"
                }, 
                "name": "Asan Medical Center"
            }, 
            "investigator": {
                "last_name": "Han Chu Lee, M.D", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Multicenter, Double-blind, Active-controlled, Randomized, Parallel Group Study to Demonstrate the Comparison and Evaluation of Baracle Tab.\u00ae and Baraclude Tab.\u00ae for HBeAG Chronic Hepatitis B", 
        "overall_contact": {
            "email": "irb@amc.seoul.kr", 
            "last_name": "Han Chu Lee, M.D", 
            "phone": "82-2-3010-7166"
        }, 
        "overall_official": [
            {
                "affiliation": "Asan Medical Center", 
                "last_name": "Han Chu Lee, M.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "The Catholic University of Korea", 
                "last_name": "Si Hyun Bae, M.D", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Gachon University of Medicine and Science Gil Medical Center", 
                "last_name": "Ju Hyun Kim, M.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Keimyung University Dongsan Medical Center", 
                "last_name": "Jae Seok Hwang, M.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Konkuk University Hospital", 
                "last_name": "So Young Kwon, M.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Kyunpook National University Hospital", 
                "last_name": "Won Young Tak", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Korae University Guro Hospital", 
                "last_name": "Jong Eun Yeon, M.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Dong-A University Hospital", 
                "last_name": "Sang Young Han, M.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Samsung Medical Center", 
                "last_name": "Joon Hyouk Lee, M.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Seoul National University Hospital", 
                "last_name": "Jung Hwan Yoon, M.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Yonsei University Severance Hospital", 
                "last_name": "Sang Hoon Ahn, M.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Ulsan University Hospital", 
                "last_name": "Neung Hwa Park, M.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Inje University", 
                "last_name": "Youn Jae Lee, M.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Chonbuk National University Hospital", 
                "last_name": "In Hee Kim, M.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Chungnam National University Hospital", 
                "last_name": "Byung Seok Lee, M.D.", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "measured at 24th week of the administration", 
            "measure": "the Difference between HBV DNA level(log10) and the base line of HBV DNA level(log10)", 
            "safety_issue": "No", 
            "time_frame": "52 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01913431"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "measured at 24th/48th week of the administration", 
                "measure": "the percentage of participants who have less than 300 copies/ml of HBV DNA (undetectable titre)", 
                "safety_issue": "No", 
                "time_frame": "52 weeks"
            }, 
            {
                "description": "measured at 24th/48th week of the administration", 
                "measure": "the proportion of participants with normalization of serum alanine aminotransferase (less than 1.0 times the upper limit of normal)", 
                "safety_issue": "No", 
                "time_frame": "52 weeks"
            }, 
            {
                "description": "HBeAg of the participants was found positive at their screening visit. Also, the measurement performs 24th/48th week of the administration.", 
                "measure": "the percentage of participants who have lost HBeAg", 
                "safety_issue": "No", 
                "time_frame": "52 weeks"
            }
        ], 
        "source": "Dong-A Pharmaceutical Co., Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Dong-A Pharmaceutical Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}